Rituximab has been used off-label in a number of conditions where evidence is limited and large, controlled trials are lacking. The policy identifies the following as unproven and not medically necessary uses: anti-GM1 antibody–related neuropathies, pure red cell aplasia, acquired factor VIII inhibitors, polyneuropathy associated with anti‑MAG antibodies, and reduction of anti‑HLA antibodies in patients awaiting renal transplant. (Reports of benefit exist, but randomized controlled trial data are not available.)

The policy also reiterates that Rituxan Hycela (rituximab with hyaluronidase) is considered unproven and not medically necessary for non‑oncology indications; oncology uses follow separate oncology coverage guidance.

The policy prohibits concurrent administration of rituximab with certain targeted immunomodulators or disease‑modifying therapies for the same indication. Examples recently added to these exclusion lists include Olumiant (baricitinib), Orencia (abatacept), Rinvoq (upadacitinib), Kevzara (sarilumab), Ultomiris (ravulizumab), and similar agents; requests for rituximab given in combination with these agents for the same condition may be denied.

Providers should confirm the patient is not receiving rituximab concurrently with listed disease‑modifying or targeted immunomodulatory agents when requesting authorization; the policy specifically notes that combination therapy for the same indication is inconsistent with coverage criteria.

The policy explicitly states that Rituxan Hycela (rituximab and hyaluronidase human) is considered unproven and not medically necessary for non‑oncology indications. For oncology indications and for any questions about Rituxan Hycela, the policy refers readers to the oncology medication clinical coverage guidance for updated NCCN‑based recommendations.

This designation applies across the non‑oncology coverage sections and is noted separately from IV rituximab products addressed in the policy.

In addition to the specific conditions listed as unproven (see previous block), the policy notes other reported but unsupported uses where randomized controlled evidence is lacking; examples cited include chronic graft‑versus‑host disease, dermatomyositis/polymyositis, and other rare immune‑mediated disorders. The document emphasizes that while case series or small studies report benefit, these uses remain not established by large, controlled trials and therefore are considered investigational for coverage purposes.

As noted, Rituxan Hycela is reiterated as unproven and not medically necessary for non‑oncology indications and is treated separately from IV rituximab products in coverage decisions.

For relapsing‑remitting multiple sclerosis (RRMS) the policy summarizes available evidence as limited and inconclusive: a Cochrane review found benefits of rituximab for RRMS remain inconclusive due to small sample sizes, short follow‑up, and risk of bias in existing studies. The policy therefore states that potential benefits need confirmation in larger, high‑quality trials before broader coverage conclusions can be drawn.

Although a phase 2 randomized trial demonstrated reductions in gadolinium‑enhancing lesions and relapse rates over 48 weeks, the policy treats MS evidence as preliminary and requiring further evaluation when considering long‑term use and coverage.

The extracted document excerpts do not present a separate, comprehensive list of explicit exclusion criteria beyond the specific product‑level and condition‑level statements already cited. In other words, there is no single, standalone block of additional exclusions in the cited chunks; exclusions are presented within sections (product‑level — e.g., Rituxan Hycela — and condition‑level lists) rather than as an omnibus exclusion list.

Readers should therefore rely on the condition‑specific and product‑specific statements throughout the policy text when determining non‑covered uses.

The policy notes a number of other reported uses for rituximab where evidence is limited; partial examples listed include anti‑GM1 antibody‑related neuropathies, pure red cell aplasia, acquired factor VIII inhibitors, polyneuropathy associated with anti‑MAG antibodies, chronic graft‑versus‑host disease, and dermatomyositis/polymyositis. These are described as conditions with case reports or small series but without large, controlled trials to establish efficacy.

Because these uses lack robust trial evidence, the policy classifies them as investigational or unproven for routine coverage consideration.

The recent policy language additions emphasize permitted, criteria‑based use (for example the new IgG4‑RD criteria) rather than presenting an exhaustive list of additional not medically necessary conditions. In the cited excerpts, the focus is on defining when rituximab is medically necessary and on product‑level statements (e.g., Rituxan Hycela NMN) rather than enumerating an expanded, long not‑medically‑necessary list.

Providers should therefore apply the condition‑specific medical necessity criteria and the product‑level exclusions in clinical authorization decisions; absence of a long NMN list in these chunks does not imply permissive coverage beyond the stated criteria.

Rituximab is a chimeric murine/human monoclonal antibody directed against the CD20 antigen on B‑lymphocytes; its Fab domain binds CD20 and the Fc domain recruits immune effector functions to mediate B‑cell lysis. This mechanism underlies its use across multiple autoimmune and immune‑mediated, non‑oncology indications.

The policy distinguishes between intravenous rituximab products (e.g., Rituxan, biosimilars) and the subcutaneous formulation combined with hyaluronidase (Rituxan Hycela), which the policy deems unproven for non‑oncology uses.

An administrative update in the policy history notes that supporting clinical evidence and references were updated and that the prior policy version (CSPA2025D0003AN) was archived; this is listed as a non‑material, informational change in the revision history.

This administrative note clarifies that literature citations and references were refreshed as part of the 11/01/2025 update but does not change clinical coverage criteria beyond the stated material revisions.